Japan's Nitto Denko establishes Nitto BioPharma to focus on pharmaceutical development

Published: 26-Jan-2016
Finance

The firm has an anti-liver fibrosis drug in clinical trials in the US, Europe and Japan


Japanese diversified materials manufacturer Nitto Denko Corporation has formed a new company to focus on pharmaceutical development.

Called Nitto BioPharma, the firm has been conducting its first anti-liver fibrosis drug programme (ND-L02-s0201), which is now in clinical trials in the US, Europe and Japan.

Osaka-based Nitto says Nitto BioPharma has several more pipelines of drugs for intractable diseases in the discovery stage.

Along with the establishment of the new company, by the middle of this year Nitto plans to set up a new facility in the Life Sciences hub in San Diego, CA, US.

Going forward, drug discovery and development ventures, such as the anti-fibrosis drug programme and others, will be conducted by Nitto and the new company.

Nitto BioPharma's activities fall into Nitto's Fine (Life Sciences) business. The firm also plans to expand its Green (Environment) and Clean (New Energy) activities.

  • Companies:
  • Nitto Denko
See more

You may also like

Manufacturing

Nitto Denko takes over Avecia Biotechnology

Read more
Boosts base in emerging nucleic acid drugs market

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Nitto Denko takes over Avecia Biotechnology

Boosts base in emerging nucleic acid drugs market
Finance

Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China

New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
Finance

Newcells Biotech raises additional funding from investors

Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
Manufacturing

ACG expands global footprint with new capsule manufacturing facility in Thailand

New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Manufacturing

£20m Scottish oligonucleotide manufacturing innovation centre now under construction

The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's biopharmaceutical presence
Subscribe now